Shares of G1 Therapeutics Inc. GTHX plunged about 52% in premarket trading on Monday after the company said it discontinued Phase 3 research assessing trilaciclib as a treatment for metastatic colorectal cancer, saying placebo outperformed the experimental therapy in the study. G1’s stock has declined 16.1% over the past three months, while the S&P 500 SPX is up 3.8%.
... Shares of G1 Therapeutics Inc. GTHX plunged about 52% in premarket trading on Monday after the company said it discontinued Phase 3 research assessing trilaciclib as a treatment for metastatic colorectal cancer, saying placebo outperformed the experimental therapy in the study. G1’s stock has declined 16.1% over the past three months, while the S&P 500 SPX is up 3.8%.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: